CP
IRD

Corbenic Partners’s Opus Genetics IRD Stock Holding History

Corbenic Partners’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-3
Closed -$1K – 197
2017
Q1 		$1K Hold
3
– – ﹤0.01% 192
2016
Q4 		$0 Hold
3
– – ﹤0.01% 217
2016
Q3 		$0 Hold
3
– – ﹤0.01% 224
2016
Q2 		$0 Hold
3
– – ﹤0.01% 190
2016
Q1 		$1K Hold
3
– – ﹤0.01% 164
2015
Q4 		$1K Hold
3
– – ﹤0.01% 182
2015
Q3 		$1K Hold
3
– – ﹤0.01% 159
2015
Q2 		$1K Hold
3
– – ﹤0.01% 139
2015
Q1 		$1K Hold
3
– – ﹤0.01% 152
2014
Q4 		$1K Hold
3
– – ﹤0.01% 216
2014
Q3 		$1K Hold
3
– – ﹤0.01% 132
2014
Q2 		$1K Hold
3
– – ﹤0.01% 105
2014
Q1 		$2K Buy
+3
New +$1.62K ﹤0.01% 100

Other funds holding IRD

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
HVIA
Hudson Valley Investment Advisors Goshen, New York $823M AUM 31.4% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return

Corbenic Partners's IRD Position: Q2 2017 in Review

Corbenic Partners sold out of Opus Genetics (IRD) in Q2 2017, closing a stake of 3 shares — an estimated $1K sold.

Corbenic Partners first reported a position in IRD in Q1 2014 and held it in 13 quarters. The position peaked at $2K in Q1 2014. 23 funds tracked by Wall St. Rank hold IRD as of Q2 2017.

  • Corbenic Partners reported no remaining Opus Genetics position as of Q2 2017 after selling out during the quarter.
  • Corbenic Partners sold 3 Opus Genetics shares in Q2 2017, an estimated $1K.
  • Corbenic Partners first reported a position in Opus Genetics in Q1 2014 and held it in 13 quarters.
  • Corbenic Partners's Opus Genetics position peaked at $2K in Q1 2014.
  • 23 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2017.

Based on Corbenic Partners's 13F filing for Q2 2017, filed 14 Aug 2017.